Boston Scientific Corporation (NYSE:BSX) is one of the 14 Best Large Cap Stocks to Invest In Now. On December 17, UBS reiterated its Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept the price target at $140. This update comes even as the shares experienced a drop over the past month. UBS analyst Danielle Antalffy believes that the risk/reward profile for Boston Scientific Corporation (NYSE:BSX) is “increasingly skewed to the upside” heading into 2026. This view is supported by the firm’s op ...

Group 1 - Boston Scientific Corporation (NYSE:BSX) is recognized as one of the best long-term stocks to buy, with UBS maintaining a Buy rating and raising the price target to $140 from $135 following strong quarterly results [1] - The company reported net revenue of $5,065 million for Q3, reflecting a 15.3% year-over-year organic growth, and adjusted earnings per share of $0.75, exceeding the consensus estimate of $0.71 [2] - Boston Scientific has increased its full-year 2025 outlook, now projecting approximately 20% growth and adjusted EPS of $3.02-$3.04, an increase from previous estimates [2] Group 2 - The FARAPULSE product line experienced approximately 63% organic worldwide expansion, with US growth improving by 40 percentage points on a comp-adjusted basis [3] - The WATCHMAN device achieved 35% organic sales growth for the fifth consecutive quarter, indicating increasing product acceptance [3] Group 3 - Boston Scientific Corporation is a global leader in manufacturing medical devices, including stents, brain stimulation systems, heart monitors, and catheters [4]